Expression of Inflammatory Mediators in Induced Sputum: A Potential Biomarker of Drug Response in COPD

Trial Profile

Expression of Inflammatory Mediators in Induced Sputum: A Potential Biomarker of Drug Response in COPD

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary) ; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 22 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top